早期辅助化疗改善肌层浸润性膀胱癌生存:系统综述与荟萃分析
该系统综述与荟萃分析纳入5项研究,评估根治性膀胱切除术后辅助化疗时机对肌层浸润性膀胱癌生存的影响。结果显示,早期辅助化疗显著改善总生存(HR 1.20 [1.06, 1.36],P=.004);45天内开始化疗的生存改善(HR 1.27 [1.02, 1.59],P=.03)大于90天内开始(HR 1.17 [1.00, 1.36],P=.04)。
要点
- 早期辅助化疗显著改善肌层浸润性膀胱癌总生存(HR 1.20 [1.06, 1.36],P=.004)。
- 45天内开始化疗的生存改善(HR 1.27 [1.02, 1.59],P=.03)大于90天内开始(HR 1.17 [1.00, 1.36],P=.04)。
- 辅助化疗时机显著影响根治性膀胱切除术后患者的生存结局。
核心结论
- 根治性膀胱切除术后辅助化疗时机显著影响肌层浸润性膀胱癌患者的生存结局,早期辅助化疗的获益凸显其在延缓疾病进展和改善长期生存方面的潜力。
研究设计与样本
- 系统检索PubMed、Cochrane Central、Scopus和Web of Science数据库,纳入探讨根治性膀胱切除术后辅助化疗时机的原始研究,共纳入5项研究。
- 采用Higgins I²%评估异质性,异质性大于50%时视为异质并使用随机效应模型,否则使用固定效应模型。
- 按辅助化疗 cutoff 时间分层,主要 cutoff 为45天和90天; cutoff 前给药定义为立即辅助化疗, cutoff 后给药定义为延迟辅助化疗,比较立即与延迟辅助化疗。
主要发现
- 所有研究均报告总生存(OS)。
- 荟萃分析显示立即辅助化疗显著改善OS,HR 1.20 [1.06, 1.36],P=.004。
- 按治疗时机分层,45天内开始化疗的生存改善(HR 1.27 [1.02, 1.59],P=.03)大于90天内开始(HR 1.17 [1.00, 1.36],P=.04)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether earlier administration of adjuvant chemotherapy (AC) can significantly augment survival rates in muscle-invasive bladder cancer. METHODS: We systematically searched PubMed, Cochrane Central, Scopus, and Web of Science library databases for original articles that looked at timing to AC after radical cystectomy. Heterogeneity was assessed using Higgins I2%, with values over 50% considered heterogeneous and analyzed with a random effects model; otherwise, a fixed effects model was used. Studies were stratified based on the cutoff time used for administering AC. Two primary cutoffs were employed: 45 days and 90 days. Immediate AC was defined as chemotherapy administered before the predefined cutoff, while delayed AC was defined as chemotherapy administered after this cutoff. Comparisons were made between immediate versus delayed. RESULTS: A total of 5 studies were included. Overall survival (OS) was reported in all of the studies. The meta-analysis showed that immediate AC significantly improved OS, with a hazard ratio (HR) of 1.20 [1.06, 1.36], P=.004. When stratifying by the timing of therapy, starting chemotherapy within 45 days resulted in a greater improvement in survival (HR 1.27 [1.02, 1.59], P=.03) compared to starting within 90 days (HR 1.17 [1.00, 1.36], P=.04). CONCLUSION: The findings of this systematic review and meta-analysis emphasize that the timing of AC post-radical cystectomy significantly influences survival outcomes in patients with MIBC. The benefits of early AC initiation underscore its potential in mitigating disease progression and improving long-term survival rates.
引用
- Kronstedt S, Saffati G, Hinojosa-Gonzalez DE, et al. Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis. Urology. 2024. PMID: 39233282. doi:10.1016/j.urology.2024.08.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。